iCAD, Inc. (NASDAQ:ICAD) Short Interest Up 28.5% in May

iCAD, Inc. (NASDAQ:ICAD - Get Free Report) was the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 397,400 shares, an increase of 28.5% from the April 30th total of 309,200 shares. Based on an average daily trading volume, of 801,800 shares, the short-interest ratio is currently 0.5 days. Approximately 1.5% of the company's stock are sold short.

Institutional Investors Weigh In On iCAD

Hedge funds and other institutional investors have recently bought and sold shares of the business. Thompson Davis & CO. Inc. acquired a new position in shares of iCAD during the 4th quarter worth $31,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in iCAD during the first quarter worth about $40,000. Goldman Sachs Group Inc. purchased a new position in iCAD in the first quarter valued at about $44,000. PKS Advisory Services LLC acquired a new stake in shares of iCAD during the 4th quarter valued at approximately $53,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of iCAD during the 1st quarter valued at approximately $71,000. Institutional investors and hedge funds own 24.61% of the company's stock.

iCAD Trading Up 1.0%

ICAD stock traded up $0.04 on Friday, hitting $3.90. The company's stock had a trading volume of 190,149 shares, compared to its average volume of 414,675. iCAD has a 1 year low of $1.18 and a 1 year high of $4.02. The stock has a market cap of $107.14 million, a price-to-earnings ratio of -30.00 and a beta of 1.38. The firm has a 50 day moving average of $3.13 and a two-hundred day moving average of $2.57.

iCAD (NASDAQ:ICAD - Get Free Report) last issued its earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.54 million.

Analysts Set New Price Targets

Several equities research analysts recently commented on ICAD shares. Craig Hallum lowered shares of iCAD from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. BTIG Research lowered iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. Wall Street Zen initiated coverage on iCAD in a report on Tuesday, May 20th. They issued a "sell" rating for the company. Finally, Laidlaw restated a "hold" rating on shares of iCAD in a research note on Thursday, April 17th.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.